Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Earns “Outperform” Rating from Wedbush

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “outperform” rating restated by Wedbush in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $40.00 target price on the stock. Wedbush’s target price would suggest a potential upside of 94.27% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Guggenheim raised their target price on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $46.50.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of Damora Therapeutics, Inc. Common Stock stock traded down $0.16 during midday trading on Tuesday, hitting $20.59. The company had a trading volume of 230,902 shares, compared to its average volume of 425,162. Damora Therapeutics, Inc. Common Stock has a 1-year low of $3.50 and a 1-year high of $38.33. The business’s 50 day simple moving average is $28.18 and its two-hundred day simple moving average is $26.27. The stock has a market cap of $1.27 billion, a PE ratio of -6.11 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. On average, sell-side analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling at Damora Therapeutics, Inc. Common Stock

In related news, CEO Jennifer Jarrett bought 12,500 shares of the company’s stock in a transaction dated Friday, September 25th. The stock was acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the acquisition, the chief executive officer owned 512,500 shares in the company, valued at approximately $10,367,875. This represents a 2.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently made changes to their positions in DMRA. Squarepoint Ops LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at about $303,000. Arizona State Retirement System bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $260,000. Seven Fleet Capital Management LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth approximately $7,398,000. Finally, Braidwell LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $42,146,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.